Early Access — free while we kick the tires
EdgarHawk

Karen Krasney

EVP, GENERAL COUNSEL

Officer

Latest: General Counsel selling · May 2026

3 filings analyzed · 1 company · Latest 2026-06-29

Never miss a filing from Karen Krasney

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
CAPRICOR THERAPEUTICS, INC. CAPR 0 3 Net selling

Activity

June 2026
medium
Sell
24,100 shares
$732,158
Significance 5/10

EVP & General Counsel Karen Krasney sells 24,100 CAPR shares at $30.38 for $732.2K; retains 30.5K shares plus 31,261 option shares.

Karen Krasney, EVP and General Counsel, sold 24,100 shares at $30.38 on 2026-06-25, reducing her direct holdings from 54.6K to 30.5K shares (-44.1% of pre-transaction holdings). This is the third open-market sale of CAPR stock by this insider; her prior CAPR sale on 2026-05-01 showed a -5.5% 30-day return, and her 2026-03-31 sale posted a -21.0% 90-day return. The stock currently trades at $23.80, down -41.0% from the 52-week high of $40.37, and has declined -20.6% over the past 30 days. The company remains unprofitable with annual revenue growth of -100.0%, though the insider retains 31,261 shares through stock options plus 30.5K direct shares post-transaction.

May 2026
2026-05-04 CAPRICOR THERAPEUTICS, INC. CAPR 10b5-1 Plan
medium
Sell
25,000 shares
$792,548
Significance 6/10

EVP General Counsel sells ~45% of holdings while simultaneously purchasing shares; net exit amid stock recovery from lows.

Krasney Karen, the company's EVP and General Counsel, executed a paired transaction—buying and selling shares on the same day—that reveals a nuanced insider posture. She purchased a meaningful stake while simultaneously liquidating roughly half her total holdings, suggesting neither bullish conviction nor bearish panic, but rather portfolio rebalancing or tax-motivated trading. What's notable is the timing: the stock has recovered significantly from its lows and is trading below its year-to-date highs, yet this C-suite officer is trimming exposure rather than adding. Against the company's challenging fundamentals—operating at a substantial net loss with no current annual revenue—this selective exit from a senior executive raises a yellow flag about near-term confidence. The transaction itself is material enough to trigger SEC thresholds, but the paired buy-sell structure muddles the interpretive signal that a straightforward sale would convey.

April 2026
2026-04-01 CAPRICOR THERAPEUTICS, INC. CAPR 10b5-1 Plan
medium
Sell
25,000 shares
$752,935
Significance 4/10

EVP General Counsel Karen Krasney sold 25,000 shares of CAPR at $30.12 (10b5-1 plan) for $752.9K; holdings fell 45.0%

Krasney sold 25,000 shares at $30.12 for $752.9K, reducing her holdings from 55,547 to 30,547 shares—a 45.0% reduction. This transaction is part of a pre-arranged 10b5-1 trading plan and therefore is scheduled rather than discretionary. Because the sale is governed by a formal plan, it reflects execution of a pre-determined schedule rather than a real-time market judgment. The scale of the reduction—nearly half her prior holdings—represents material portfolio action by a senior legal executive, though the non-discretionary nature limits inference about current company conditions or insider conviction.

Related insiders